Announcement of Approval for Listing of Shares of PHC Holdings Corporation on the Tokyo Stock Exchange

September 7, 2021

PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President & CEO: John Marotta) has today announced the approval by Tokyo Stock Exchange, Inc. (the “TSE”) for the listing of the shares of its common stock (the “shares”) on the First Section of TSE. The scheduled date for the listing of the shares is Thursday October 14, 2021, on or after which date the shares will be available for trading on the TSE.

IMPORTANT NOTICE:
This document is a press release prepared for the sole purpose of public announcement and is not prepared for the purpose of soliciting investment or engaging in any other similar activities thereto, whether within or outside Japan. In the event of making an investment in Japan, please carefully review the prospectus (including any amendments thereto) prepared by us and make an independent investment decision.

In addition, this press release is not an offer of securities for sale in the United States. The shares may not be offered or sold in the United States absent registration or an exemption from requirement. If any public offering of the shares is made in the United States, it will be by means of a prospectus that may be obtained from us or the selling shareholders and that will contain detailed information about us and our management, as well as our financial statements.

About Epredia

Epredia is a global leader in the anatomical pathology field, providing comprehensive solutions for precision cancer diagnostics and tissue diagnostics. Powered by key brands, including Erie Scientific, Menzel-Gläser, Microm, Shandon, and Richard-Allan Scientific, Epredia’s portfolio includes microscope slides, instruments and consumables. Epredia was established following the acquisition of Thermo Fisher Scientific’s Anatomical Pathology business by PHC Holdings in 2019. Epredia has major sites in the United States, the United Kingdom, Germany, Switzerland and China with a total of around 1,200 employees. Epredia is committed to achieving its mission to improve lives by enhancing cancer diagnostics for patients around the world. For further information on Epredia and its products, please visit www.epredia.com.

About PHC Holdings Corporation

Company Name: PHC Holdings Corporation
Representative: President, CEO John Marotta
Incorporation: March 31, 2014
Headquarters: 2-38-5 Nishishimbashi, Minato-ku, Tokyo, Japan
www.phchd.com

For more information, please contact: